产品描述

Enzalutamide, also known as MDV3100, is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. In August 2012, the United States (U.S.) Food and Drug Administration (FDA) approved enzalutamide for the treatment of castration-resistant prostate cancer.

化学结构

化学名称

4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide

SMILES Code

O=C(NC)C1=CC=C(N(C(N2C3=CC=C(C#N)C(C(F)(F)F)=C3)=S)C(C)(C)C2=O)C=C1F

基本信息

产品编号:XM700  产品名称:Enzalutamide (MDV3100)  别名:MDV3100; MDV 3100; MDV-3100; Enzalutamide brand name: Xtandi.  CAS#:915087-33-1  分子式:C21H16F4N4O2S  精确分子量:464.09301  分子量:464.43  纯度:>98%

物化性质

该产品只供科研使用，不能给病人提供。